Fadebi Olalekan Olatunde, Miya Thabiso Victor, Khanyile Richard, Dlamini Zodwa, Marima Rahaba
SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.
Department of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield 0028, South Africa.
Noncoding RNA. 2025 Jan 29;11(1):9. doi: 10.3390/ncrna11010009.
Breast cancer is one of the leading causes of mortality among women, primarily due to its complex molecular landscape and heterogeneous nature. The tendency of breast cancer patients to develop metastases poses significant challenges in clinical management. Notably, mutations in the breast cancer gene 1 () significantly elevate breast cancer risk. The current research endeavors employ diverse molecular approaches, including RNA, DNA, and protein studies, to explore avenues for the early diagnosis and treatment of breast cancer. Recent attention has shifted towards long non-coding RNAs (lncRNAs) as promising diagnostic, prognostic, and therapeutic targets in the multifaceted progression of breast cancer. Among these, long intergenic non-coding RNAs (lincRNAs), a specific class of lncRNAs, play critical roles in regulating various aspects of tumorigenesis, including cell proliferation, apoptosis, epigenetic modulation, tumor invasion, and metastasis. Their distinctive expression patterns in cellular and tissue contexts underscore their importance in breast cancer development and progression. Harnessing lincRNAs' sensitivity and precision as diagnostic, therapeutic, and prognostic markers holds significant promise for the clinical management of breast cancer. However, the potential of lincRNAs remains relatively underexplored, particularly in the context of -mutated breast cancer and other clinicopathological parameters such as receptor status and patient survival. Consequently, there is an urgent need for comprehensive investigations into novel diagnostic and prognostic breast cancer biomarkers. This review examines the roles of lincRNAs associated with in the landscape of breast cancer, highlighting the potential avenues for future research and clinical applications.
乳腺癌是女性死亡的主要原因之一，主要是由于其复杂的分子格局和异质性。乳腺癌患者发生转移的倾向给临床管理带来了重大挑战。值得注意的是，乳腺癌1号基因（）的突变显著增加了乳腺癌风险。当前的研究努力采用多种分子方法，包括RNA、DNA和蛋白质研究，以探索乳腺癌早期诊断和治疗的途径。最近的注意力转向了长链非编码RNA（lncRNAs），它们有望成为乳腺癌多方面进展中的诊断、预后和治疗靶点。其中，长链基因间非编码RNA（lincRNAs）作为lncRNAs的一类特定分子，在调节肿瘤发生的各个方面发挥着关键作用，包括细胞增殖、凋亡、表观遗传调控、肿瘤侵袭和转移。它们在细胞和组织环境中的独特表达模式突出了其在乳腺癌发生和发展中的重要性。利用lincRNAs作为诊断、治疗和预后标志物的敏感性和精确性，对乳腺癌的临床管理具有重大前景。然而，lincRNAs的潜力仍相对未被充分探索，特别是在乳腺癌基因1突变的背景以及其他临床病理参数如受体状态和患者生存方面。因此，迫切需要对新型乳腺癌诊断和预后生物标志物进行全面研究。本综述探讨了与乳腺癌基因1相关的lincRNAs在乳腺癌格局中的作用，突出了未来研究和临床应用的潜在途径。
